Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
about
A modified formula for calculating low-density lipoprotein cholesterol values.LDL-cholesterol: Friedewald calculated versus direct measurement-study from a large Indian laboratory databaseDistribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006Translating cholesterol guidelines into primary care practice: a multimodal cluster randomized trial.Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis.Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--EffectiveThe impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy.Does LDL-C Estimation Using Anandaraja's Formula Give a Better Agreement with Direct LDL-C Estimation than the Friedewald's Formula?Comparative evaluation of flavone from Mucuna pruriens and coumarin from Ionidium suffruticosum for hypolipidemic activity in rats fed with high fat dietNigerian Honey Ameliorates Hyperglycemia and Dyslipidemia in Alloxan-Induced Diabetic Rats.Increasing Oxidative Stress with Progressive Hyperlipidemia in Human: Relation between Malondialdehyde and Atherogenic Index.Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool.Ethanol extract of Zhongtian hawthorn lowers serum cholesterol in mice by inhibiting transcription of 3-hydroxy-3-methylglutaryl-CoA reductase via nuclear factor-kappa B signal pathway.Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.Racial disparities in lipid control in patients with diabetes.Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis.Anti-oxidant and anti-hyperlipidemic activity of Hemidesmus indicus in rats fed with high-fat diet.Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States.Clinical review: impact of statin substitution policies on patient outcomes.Role of free radical in atherosclerosis, diabetes and dyslipidaemia: larger-than-life.Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up-regulating the gene expression of PPAR-α in hypercholesterolemic rats induced with a high-cholesterol diet.Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy.Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.Ligusticum chuanxiong Prevents Ovariectomy-Induced Liver and Vascular Damage in Rats
P2860
Q33933946-E0F0710E-3CB5-460B-9029-7E14CE27F7CDQ34069257-816A12F9-40DC-4FA4-A6CF-D24482F416E3Q34683471-2DDE35A3-5507-4A32-96D7-D5E878BF7179Q35655037-AA225DC6-6D1E-4675-9236-F4856BE49EC5Q35694196-FAE64802-E71C-480F-B2B7-821D4796E3F6Q35793619-9755BA92-163B-4D7F-A201-F52BE39B8AC9Q35922120-95BD5CF4-726E-4853-A079-06CA7CB3D9D2Q35980572-03C131C1-2869-45D6-8FA5-245E50A309CFQ36423454-A3FFC29E-763E-4DDB-9ACC-1787F54EABB1Q36731956-B5A79D8F-E78D-468A-92A7-2BD9762C50ABQ36969011-1BFEA277-0A6A-460F-BEB9-C76322858E47Q37071583-B2001950-4CFD-41F0-BA01-E7A7C31D7A27Q37107089-E1B4ADB8-210E-4341-B3D8-7A99589B3E73Q37151316-0D6E0067-68E8-4DD5-8341-AC7B16EBC7C7Q37154916-7B821E0A-6318-4221-B660-E3450E82992BQ37223505-A5131902-1880-4BF6-A65E-68704E86229CQ37314368-2D31912B-8912-414D-B0CB-F6CF4050FA5EQ37379176-825DFAA5-4C3D-4B95-9BD8-E3BBDA6F7B9AQ37384820-3C6A26D8-D1BA-4A60-BC9A-335F94372B89Q38213250-7E98EB80-BE15-4B36-8D99-606BC442D24DQ43525437-F3D33F5D-C5D8-46B1-820B-1F04670F808FQ45331634-F9E4C766-3F9B-4F1D-BF65-E52457D6EB96Q46049651-175C80B2-A284-4F50-B614-C41D8BAC432AQ57590261-F1E267E6-C87D-4A93-898E-6334A5EFD3A0
P2860
Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Implications of cardiac risk a ...... amination Survey 1999 to 2002.
@ast
Implications of cardiac risk a ...... amination Survey 1999 to 2002.
@en
type
label
Implications of cardiac risk a ...... amination Survey 1999 to 2002.
@ast
Implications of cardiac risk a ...... amination Survey 1999 to 2002.
@en
prefLabel
Implications of cardiac risk a ...... amination Survey 1999 to 2002.
@ast
Implications of cardiac risk a ...... amination Survey 1999 to 2002.
@en
P2093
P1433
P1476
Implications of cardiac risk a ...... amination Survey 1999 to 2002.
@en
P2093
Jon G Keevil
Michael W Cullen
Patrick E McBride
P304
P356
10.1161/CIRCULATIONAHA.106.645473
P407
P577
2007-03-12T00:00:00Z